[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"head-and-neck-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:head-and-neck-cancers":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,41,70,90,129,153,180,207,248,277,339,365,395,427,453,472,495,529,554,582],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100100354","identification-of-secreted-markers-for-tumor-hypoxia-in-patients-with-head-and-neck-or-lung-cancers-100100354",false,"NCT00568490","Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers","Inclusion Criteria:\n\n* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.\n* Able to sign a Stanford IRB approved consent form\n\nExclusion criteria:\n\n* Refuse or unable to sign an IRB approved consent form.\n* Refuse to be contacted in the future for follow up.","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.",[23,24,25,26,27],"Head and Neck Cancer","Lung Cancer","Lip Cancer","Lip Neoplasms","Head and Neck Cancers","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":32},"1998-09-01",{"date":36,"type":19},"2027-06-30",{"name":38,"class":39},"Stanford University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":40},"100645028","impact-of-hmb-supplementation-on-inflammation-and-outcomes-in-head-and-neck-cancer-100645028","NCT07675421","Impact of HMB Supplementation on Inflammation and Outcomes in Head and Neck Cancer","Impact of Beta Hydroxy Methyl Butyrate (HMB) Supplementation on Inflammatory Markers and Clinical Outcomes in Patients With Head And Neck Cancer","Inclusion Criteria:\n\n* Individuals aged 18 years or older;\n* Both sexes (male and female);\n* Patients treated at the outpatient clinic for head and neck carcinoma;\n* Indication for potentially curative tumor resection surgery.\n\nExclusion Criteria:\n\n* Diagnosis of cancer of the face, skin, paranasal sinuses, or thyroid;\n* Undergoing neoadjuvant or palliative treatment;\n* Cognitive or intellectual impairment that may hinder proper understanding of the study;\n* Refusal to participate or to sign the informed consent form.",{"count":49,"type":19},66,"INTERVENTIONAL",[52],"NA","Cancer patients undergoing surgery are at high risk of malnutrition due to the effects of the tumor and surgical stress, which can lead to worse clinical outcomes. This study aims to evaluate the impact of beta-hydroxy-beta-methylbutyrate (HMB) supplementation on inflammatory markers and clinical outcomes in patients with malignant tumors of the upper airways and digestive tract undergoing surgery.\n\nThis is a randomized, double-blind clinical trial. Participants will be randomly assigned to one of two groups: intervention (3 g\u002Fday of HMB) or control (3 g\u002Fday of maltodextrin) for 30 days prior to surgery. Initial assessments will include nutritional status, muscle strength, quadriceps muscle thickness by ultrasound, and laboratory tests. Postoperative clinical outcomes will be monitored through electronic medical records.",[27],[56,57,58,59,60],"Head and Neck Neoplasms","Surgery","Inflammation","Muscle Mass","Postoperative Complications","2026-06-26",{"date":63,"type":32},"2026-06-30",{"date":65,"type":19},"2026-08-01",{"date":67,"type":19},"2027-11-30",{"name":69,"class":39},"Federal University of Minas Gerais",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":50,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100584983","innovative-osa-screening-in-head-and-neck-cancer-patients-with-the-apneal-app-100584983","NCT06896448","Innovative OSA Screening in Head and Neck Cancer Patients With the Apneal App","Inclusion Criteria:\n\n* Adult patients undergoing diagnostic workup for a lesion suspected to be a head and neck cancer, followed by confirmation of the malignant nature of the lesion. The following locations will be included: the nasopharynx, nasal cavities, sinuses, oral cavity, oropharynx, hypopharynx, larynx, and parotid gland.\n* The collection of the informed consent signature is required.\n* The patient must be affiliated with the social security system.\n\nExclusion Criteria:\n\n* Minor patients, or those under judicial protection, guardianship, or curators.\n* Lack of confirmation of the malignant nature of the lesion.\n* Diagnosis of metastatic cancer.\n* Known history of obstructive sleep apnea syndrome (OSAS) or previously treated head and neck cancer.",{"count":5,"type":19},[52],"Obstructive sleep apnea syndrome is a common but often underdiagnosed condition, with significant impacts on quality of life, such as fatigue, attention disorders, and an increased risk of heart attack or stroke. Structural changes in the head and neck region appear to contribute to the onset or worsening of this condition.\n\nTo improve patients' quality of life, early diagnosis is essential. Currently, diagnosis relies on expensive devices, often associated with long waiting times. To address these challenges, an innovative solution is proposed: a smartphone application enabling a simple and accessible diagnosis. This application is currently under validation and has not yet been commercialized.\n\nThe purpose of the study is to determine whether this smartphone application can be used in clinical practice for patients with a head and neck lesion to diagnose sleep apnea syndrome and to assess its progression during the medical care. This study is for patients who present a head and neck lesion currently under evaluation in our department at Caen University Hospital.\n\nThis research will be integrated into routine follow-up for a period of six months.\n\nThe medical device used in this study, Apneal, is a smartphone application currently undergoing validation for the rapid diagnosis of sleep apnea syndrome. Its use is simple: the smartphone is placed in airplane mode and secured to the chest overnight. Using the phone's built-in sensors, respiratory sleep data is collected and analyzed.\n\nAs part of the initial assessment, a dedicated sleep consultation is included, during which a few questionnaires are completed, followed by an overnight sleep recording using the Apneal application. This will be conducted at the beginning of the care during the assessment phase and again six months after the completion of any potential treatment.\n\nDepending on the results, if they are inconclusive, an additional sleep recording may be required using a ventilatory polygraphy device.\n\nThis study involves only two overnight recordings with a smartphone secured to the chest, which we will set up during the consultation.",[80,27],"Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)","2026-06-17",{"date":83,"type":32},"2026-06-18",{"date":85,"type":32},"2025-09-16",{"date":87,"type":19},"2027-09-16",{"name":89,"class":39},"University Hospital, Caen",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":50,"phases":99,"briefSummary":101,"conditions":102,"keywords":116,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100628495","phase-1-a-phase-1-study-of-epi-326-in-egfr-mutant-nsclc-and-hnscc-100628495","NCT07462377","A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC","A First-in-Human, Open-label, Multicenter, Phase 1 Study of EPI-326 in Patients With Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Participant has a life expectancy \\> 12 weeks at Day 1.\n2. Participant has an ECOG performance status of 0-2.\n3. Participant has pathologically confirmed NSCLC or HNSCC.\n\n   o For NSCLC: the tumor harbors any documented EGFR mutation, insertion, or deletion.\n4. Participant has locally advanced or metastatic NSCLC or HNSCC.\n5. Participant has adequate organ function\n\nExclusion Criteria:\n\n1. Participant has history of uncontrolled illness.\n2. Participant has symptomatic brain metastases.\n3. Participant has a diagnosis of any secondary malignancy within 3 years prior to enrollment, except for those patients treated with curative intent and no evidence of active disease.",{"count":98,"type":19},110,[100],"PHASE1","A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.",[103,104,105,106,107,108,109,23,27,110,111,112,113,114,115],"Epidermal Growth Factor","Epidermal Growth Factor Receptor","Epidermal Growth Factor Receptor Gene Mutation","Non Small Cell","Non Small Cell Lung","Non Small Cell Lung Cancer","Head and Neck","Head and Neck Squamous Cell Cancer","Head and Neck Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma HNSCC","NSCLC (Non-small Cell Lung Cancer)","HNSCC","EGFR",[111,114,105,115,108,117],"NSCLC","2026-06-08",{"date":120,"type":32},"2026-06-10",{"date":122,"type":32},"2026-03-31",{"date":124,"type":19},"2029-07",{"name":126,"class":127},"EpiBiologics","INDUSTRY",6,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":151,"locationsCount":40},"100637601","the-role-of-dietary-fiber-in-mitigating-sarcopenia-risk-in-head-and-neck-cancer-100637601","NCT07622914","The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer","A Preliminary Elucidation of the Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer","Inclusion Criteria:\n\n* ≥18 years of age\n* Newly diagnosed with squamous cell carcinoma of the: paranasal sinuses, nasal cavity, oral cavity, tongue, larynx, pharynx \\[i.e., nasopharynx, oropharynx, hypopharynx\\]\n* Meeting at least 60% of baseline energy needs\n* Willingness to provide data prior to treatment\n* Access to the internet\n* Access to a home freezer\n* Ability to do remote interview\n* Access to a phone\n* Willingness to avoid pre-, pro-, or synbiotics\n\nExclusion Criteria:\n\n* Previously diagnosed or positive screen for a GI-related condition or eating disorder\n* Able to complete bioelectrical impedance (stand unsupported, no pacemaker or limb amputation) and Timed Chair Stands\n* Currently pregnant, planning to become pregnant, or breastfeeding\n* Current or past 3-month antibiotic use",{"count":137,"type":19},59,"Emerging data suggest consumption of dietary fiber before and during cancer treatment may improve prognosis for patients with head and neck cancer, in part via increased production of short chain fatty acids, systemic anti-inflammatory effects, and decreased risk of sarcopenia. Foods rich in dietary fiber are often low in calories and protein, thus are not typically targeted in current treatment paradigms that focus on countering the catabolic state associated with sarcopenia. This project entails an observational, mixed methods study to: observe dietary fiber intake in patients with head and neck cancer from time of diagnosis for six months; elucidate the relationship between dietary fiber intake, short chain fatty acids, inflammatory markers, and sarcopenia; and explore the feasibility of and patient perceptions regarding promoting dietary fiber as part of their treatment approaches.",[27],[141,142,143,144],"Head and neck cancer","Diet","Sarcopenia","Dietary fiber","2026-05-27",{"date":147,"type":32},"2026-06-03",{"date":149,"type":32},"2025-10-31",{"date":36,"type":19},{"name":152,"class":39},"University of Oklahoma",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":50,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100611491","spect-ct-guided-elective-contralateral-neck-treatment-in-lateralized-oropharyngeal-cancer-100611491","NCT07241273","SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer","SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer: A Phase II Trial","SELECT-FR","Inclusion Criteria:\n\n1. Patients must have signed a written informed consent form prior to any trial specific procedures.\n2. Patients with histologically confirmed T1-T3 M0 lateralized OPC (tonsil, soft palate, pharyngeal wall or base of tongue) not involving or crossing midline. Nodal disease may include no node or single or multiple ipsilateral lymph nodes (largest should be equal or less than 6 cm in maximum diameter) without contralateral nodes involved. For HPV-positive patients, this includes N0-N1. For HPV-negative patients, this includes N0-N2b. Patients with radiologic extranodal extension without clinical signs of extranodal extension (skin invasion, deep nodal fixation, and\u002For clinical signs of cranial nerve or brachial plexus invasion) will be eligible for participation.\n3. HPV-positive or -negative (by p16 immunohistochemistry). Tumours will be classified as p16 at local sites based on greater than 70% strong diffuse nuclear or nuclear and cytoplasmic staining.\n4. Planned definitive bilateral neck radiotherapy with or without concurrent chemotherapy.\n5. Patients ≥ 18 years old.\n6. ECOG Performance Status 0-1.\n7. The following radiological investigations must have been done within 8 weeks before randomization:\n\n   * CT or MRI of the neck (with head imaging as indicated);\n   * PET-CT scan;\n   * Chest CT scan.\n8. Patients who receive a concomitant chemoradiotherapy (cCRT) should have adequate organ and bone marrow function including the following:\n\n   * Hematological function (absolute neutrophil count ≥ 1.5 x10⁹\u002FL, platelets ≥ 100 x10⁹\u002FL, hemoglobin ≥ 9 g\u002FdL) measured before cCRT.\n   * Renal function (creatinine clearance ≥ 50 mL\u002Fmin per Cockcroft and Gault formula) measured before cCRT.\n   * Hepatic function (total bilirubin \\\u003C 1.5 ULN, Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) \\\u003C 2.5 ULN, Alkaline phosphatase \\\u003C 2.5 ULN) measured before cCRT.\n9. Women\u002Fmen of childbearing potential must have agreed to use a highly effective contraceptive method up to 90 days after completing radiotherapy.\n\n   Women of childbearing potential must have a negative pregnancy test before the beginning of the trial.\n10. Treating surgeon must confirm that the patient is a candidate to undergo injection procedure for lymphatic mapping in either the nuclear medicine, ambulatory clinic, or operating room setting.\n11. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.\n12. Patients affiliated to (or beneficiary from) the French social security system.\n13. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n\nExclusion Criteria:\n\n1. Patients with T1-T2 cancers isolated to the tonsil fossa (i.e., without any soft palate, tongue base, posterior pharyngeal wall or posterior tonsil pillar involvement) with no involved lymph nodes or with a single ipsilateral node \\\u003C 3 cm without extranodal extension.\n2. Patients with tonsil or tongue base primary squamous cell carcinoma who have previously undergone diagnostic palatine or lingual tonsillectomy with either complete excision or with no clinically apparent residual disease are excluded. However, patients who have had previous deep biopsies or partial excisions with clinically evaluable disease are still eligible.\n3. Previous head and neck cancer or multiple synchronous primary head and neck cancers.\n4. Previous induction or neo-adjuvant chemotherapy.\n5. Previous radiation therapy to the head and neck or comprehensive neck dissection of at least 3 levels on either side (due to potential for disrupted lymphatic channels and drainage pathways). Patients who have had excisional biopsies of involved lymph nodes are, however, still eligible.\n6. Previous radiotracer allergy. Contraindication in patients with history of hypersensitivity to human albumin-containing products.\n7. Patients with severe, active co-morbidity including any of the following:\n\n   * Chronic Obstructive Pulmonary Disease or other pulmonary illness requiring hospitalization within 30 days of registration.\n   * Unstable angina and\u002For congestive heart failure requiring hospitalization within the 30 days of registration.\n   * Acute myocardial infarction within 30 days of study registration.\n   * Diseases precluding RT (e.g., scleroderma).\n8. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, as assessed by the investigator.\n9. Pregnant or breastfeeding women.\n10. Patient enrolled in another therapeutic trial within 30 days of registration.\n11. Persons deprived of their liberty or under protective custody or guardianship.",{"count":162,"type":19},128,[52],"Oropharyngeal cancer (OPC) is the most common type of head and neck cancer. The current standard treatment for this cancer is radiotherapy (RT) of the tumour and lymph nodes of both sides of the neck, combined with concurrent chemotherapy for advanced stages. Even though a small proportion of patients with this cancer have involvement of the lymph nodes of the neck on the opposite side of the tumour (contralateral involvement) or involvement of the lymph nodes on both sides of the neck (bilateral involvement), bilateral radiotherapy is performed due to the risk of contralateral microscopic involvement, which is invisible on imaging and clinical examination. Bilateral radiotherapy causes more adverse events, leading to a decrease in quality of life.\n\nLymphatic mapping using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging is a technique that visualises the lymphatic drainage of the tumour and thus determines whether radiotherapy should be delivered unilaterally or bilaterally to the lymph nodes. This technique would therefore reduce adverse events and improve quality of life, while maintaining the efficacy of radiotherapy.\n\nThe goal of the clinical trial SELECT-FR is to investigate if the efficacy of a lymphatic drainage mapping with a SPECT-CT-guided approach is acceptable in terms of two-year Disease Free Survival (DFS) rate in patients with lateralized OPC.",[166,167,168,109,23,27],"Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Cancers","Oropharyngeal Carcinoma","NOT_YET_RECRUITING","2026-03-23",{"date":172,"type":32},"2026-03-24",{"date":174,"type":19},"2026-04",{"date":176,"type":19},"2031-04",{"name":178,"class":39},"UNICANCER",12,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":50,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100568438","feasibility-study-of-cbct-for-igrt-in-cancer-patients-100568438","NCT06681233","Feasibility Study of CBCT for IGRT in Cancer Patients","A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients","Inclusion Criteria:\n\n1. Patient age ≥ 18\n2. Patient is receiving radiation therapy for head and neck, thorax, liver, breast, genitourinary, or gastrointestinal malignancies\n3. A CBCT acquisition for localization is standard of care for the radiation therapy treatment plan being delivered\n\nExclusion Criteria:\n\n1. Patient has ECOG Performance Status ≥3.\n2. Patient is wheelchair bound.\n3. Patient has a life expectancy \\\u003C3 months.\n4. Patient is unwilling or unable to provide informed consent to participate in the study.\n5. Patient is pregnant or has plans for pregnancy during the period of treatment.\n6. Patient is part of a vulnerable population (per ISO 14155:2020, \"individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response\"). This includes prisoners.",{"count":188,"type":19},50,[52],"Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow.\n\nVarian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image.\n\nThis study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments.\n\nThe goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.",[27,192,193,194,195,196],"Breast Cancer","Thoracic Cancers","Liver Cancer","Genito Urinary Cancer","Gastrointestinal Cancers","2026-03-12",{"date":199,"type":32},"2026-03-13",{"date":201,"type":32},"2025-02-19",{"date":203,"type":19},"2026-09",{"name":205,"class":127},"Varian, a Siemens Healthineers Company",4,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":50,"phases":216,"briefSummary":217,"conditions":218,"keywords":232,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":128},"100586075","phase-1-idov-immune-for-advanced-solid-tumors-100586075","NCT06910657","IDOV-Immune for Advanced Solid Tumors","A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists.\n* ECOG performance status ≤ 1.\n* Measurable disease per RECIST v1.1.\n* Adequate organ and bone marrow function.\n* At least 28 days since major surgery, prior immunotherapy, or radiotherapy (with exceptions for minor procedures).\n* Negative pregnancy test for women of childbearing potential.\n* Agreement to use effective contraception during treatment and for 3 months after.\n* Ability to provide informed consent and comply with study requirements.\n\nKey Exclusion Criteria:\n\n* Prior treatment with an oncolytic virus.\n* Active or recent vaccinia virus infection or smallpox\u002Fmonkeypox vaccination within 10 years.\n* Active uncontrolled infection requiring systemic treatment.\n* History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria).\n* Unresolved ≥ Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions).\n* Active or symptomatic autoimmune disease requiring systemic therapy.\n* Active or untreated CNS metastases (unless stable per protocol).\n* Significant cardiac disease (e.g., NYHA Class III\u002FIV heart failure).\n* Interstitial lung disease or prior pneumonitis requiring steroids.\n* Conditions requiring chronic immunosuppressive therapy.\n* Severe skin disorders or history of pancreatitis.\n* Bleeding disorders or history of recent serious thromboembolic events.\n* Any medical or psychiatric condition that could interfere with study participation.",{"count":215,"type":19},78,[100],"This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor.\n\nThe purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors.\n\nParticipants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer.\n\nThis study is being conducted at multiple sites in the United States and Australia.",[219,220,221,222,223,224,225,226,192,227,228,24,229,230,27,231],"Colorectal Cancer","Pancreatic Cancer","Melanoma","Ovarian Cancer","Gastric Cancer","Esophageal Cancer","Hepatocellular Carcinoma","Renal Cell Carcinoma","Sarcoma","Bladder Cancer","Prostate Cancer","Cervical Cancers","Adrenal Gland Tumors",[233,234,235,236,237,238],"Oncolytic Virus Therapy","Advanced Solid Tumors","Metastatic Cancer","Refractory Cancer","Immunotherapy","Vaccinia Virus","2026-02-27",{"date":241,"type":32},"2026-03-02",{"date":243,"type":32},"2025-08-25",{"date":245,"type":19},"2027-05-31",{"name":247,"class":127},"ViroMissile, Inc.",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":276},"100626568","food-related-quality-of-life-in-patients-with-cancer-100626568","NCT07437326","Food-related Quality of Life in Patients With Cancer","Modeling the Influence of Pathological Factors, Oral Symptoms and Sensory Perception on Food-related Quality of Life in Patients With Cancer","QVA-Mod","Inclusion Criteria:\n\n* Patient aged 18 years or older;\n* Patient with gastrointestinal, breast, gynecologic, head and neck, lung\n* Patient receiving a cancer treatment (chemotherapy, targeted therapy, immunotherapy, etc.) from at least two months;\n* Patients having undergone anticancer treatment (chemotherapy, targeted therapy, immunotherapy, etc.) having completed it at least 3 months and no more than 12 months before inclusion;\n* Patient capable of filling a questionnaire;\n* Patient having given his free, informed and express consent.\n\nExclusion Criteria:\n\n* \\- Patient having a radiotherapy treatment for a head or neck cancer;\n* Patient having presented nausea and vomiting during the last 24 hours;\n* Patient with severe inflammation of the mouth or throat (ulcers, mucus);\n* Patient with cognitive disorders and memory loss;\n* Pregnant women or breastfeeding;\n* Adult under legal protection (guardianship, curatorship).",{"count":257,"type":19},180,"Food plays a fundamental role in quality of life. In patients with cancer psychological burden and treatment-related side effects can impact appetite, taste perception and pleasure of eating, making nutritional management more challenging.\n\nGiven the central role of food and nutrition in maintaining physical health and psychological well-being, it is essential to better understand the factors that contribute to food-related quality of life in order to improve the quality of life of patients with cancer. Despite the importance of these psychological aspects, current assessments tools do not adequately measure the impact of cancer on the food-related quality of life.\n\nIn a study entitled \"CANUT-QVA\" a specific questionnaire measuring nine dimensions of food related quality of life was developed, allowing for a better understanding of how patients perceive and experience their diet. This instrument consists of 46 items and explores nine dimensions, its use showing a significant decrease in food related quality of life of patients with breast cancer, opening the way for targeted interventions to improve nutritional well being and overall quality of life in cancer patients.\n\nThe present study aims to analyse various factors - such as oral health, sensory profile and clinical characteristics - associated with food-related quality of life in patients with cancer (gastrointestinal, head and neck, lung, breast and gynecologic cancer) during or after treatment, in order to develop a predictive model of food related quality of life. The main objective of this project is to identify the population at highest risk, so as to better tailor nutritional interventions for patients with cancer, considering both the type of treatment received and the phase, during or after treatment. The food-related quality of life questionnaire containing 46 items will be used to measure the primary outcome.",[192,27,260,261,24],"Gynecologic Cancer","Gastrointestinal Cancer",[263,264,265,266,267],"cancer","food","nutrition","perceptions","quality of life related to food","2026-02-20",{"date":239,"type":32},{"date":271,"type":19},"2026-03",{"date":273,"type":19},"2027-09",{"name":275,"class":39},"Hospices Civils de Lyon",3,{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":50,"phases":287,"briefSummary":289,"conditions":290,"keywords":310,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":338},"100328442","phase-1-vmd-928-monotherapy-and-in-combination-with-pembrolizumab-to-treat-trka-overexpression-driven-solid-tumors-or-lymphoma-100328442","NCT03556228","VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","A Phase 1\u002F2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma","Key Inclusion Criteria:\n\n#. Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma:\n\nPhase 1 Dose Escalation only: Subjects with\n\n(A) any advanced solid tumors of\n\n1. Head and Neck Cancers (\"HNC\") (of any types),\n2. Esophageal cancer,\n3. Lung cancers (of any types),\n4. Mesothelioma,\n5. Pancreatic cancers,\n\nOr,\n\n(B) any NTRK1 gene fusion positive (\"NTRK1+\") solid tumors or lymphomas, that is relapsed, refractory or intolerant (R\u002FR\u002FI) to standard of care (SOC) and for which there is no approved or curative therapy. Additionally, patients must not be candidates for or have exhausted regimens known to provide clinical benefit, including hematopoietic stem cell transplantation in lymphoma patients if they are deemed transplant eligible.\n\nPhase 2 Monotherapy and Combination with Pembrolizumab only:\n\nSubjects must have\n\n1. TrkA-driven HNC, Esophageal, Lung, Mesothelioma, Pancreatic cancers; or,\n2. any NTRK1+ solid tumors or lymphoma\\*, that is R\u002FR\u002FI to SOC.\n\nKey Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 or 1.\n* Able to swallow and retain oral medication.\n* Subjects must either have available archival tumor tissue samples, or consent to tumor tissue sampling prior to the first dose.\n* Adequate organ system function as defined as follows:\n\n  1. Absolute neutrophil count ≥1.5x10\\^9\u002FL\n  2. Hemoglobin ≥9g\u002FdL\n  3. Platelets ≥100x10\\^9\u002FL\n  4. PT\u002FINR, PTT ≤1.5xULN\n  5. Total bilirubin ≤1.5x ULN\n  6. AST, ALT ≤2.5xULN\n  7. Creatinine ≤1.2xULN for age, weight\n  8. Calculated creatinine clearance or 24h urine creatinine clearance ≥60mL\u002Fmin\n\nKey Exclusion Criteria:\n\n* Received chemotherapy having delayed toxicity within the last 14 days (six weeks for prior nitrosourea or mitomycin C).\n* Received anticancer therapy with radiation, immunotherapy, and a biologic, surgery and\u002For tumor embolization within the past 2 weeks.\n* Received an investigational anticancer drug within 14 days or 5 half-lives of the investigational agent, whichever is longer, prior to the first dose of VMD-928. Any exceptions to the above must be approved by the Sponsor Medical Monitor.\n* Unresolved toxicity from previous anticancer therapy \\> CTCAE Grade 1 (except alopecia or anemia) unless agreed to by both the Sponsor Medical Monitor and the Investigator.\n* Known active infections including HIV disease.\n* Currently pregnant, nursing, or planning to become pregnant during the course of the study.\n* QTcF interval ≥ 480 msec.\n* Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.\n* Acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks.\n* Unstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would compromise the patient's safety or interfere with assessment of the drug.\n* Psychological, familial, sociological, geographical, or other concurrent conditions that would interfere with safety evaluation, limit the patient's ability to follow the procedures in the protocol or otherwise jeopardize compliance with the protocol. Patients with uncontrolled major depression, bipolar disorder, or severe anxiety disorder are excluded.\n* Patient has had or is currently having other malignant tumors within 3 years.\n* Patients have multiple factors that affect their oral medication.\n* Patients have long-term unhealed wounds or fractures.\n* Patients have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage.\n* Patients are taking the following drugs and can't stop them during the study:\n\n  * Tylenol or medicine containing acetaminophen (paracetamol).\n  * Antacids (e.g. TUMS, calcium carbonate, or magnesium hydroxide), proton pump inhibitors (e.g. omeprazole), H2 blockers (e.g. famotidine), or buffered vitamins.\n* Epstein-Barr virus (EBV) negative nasopharyngeal carcinoma.\n\nFor Phase 2 only:\n\n* Negative result on TrkA immunohistochemistry (IHC) assay.\n* Have visceral crisis, defined as severe organ dysfunction and rapid progression of the cancer. (It is not about presence of visceral metastasis.)\n\nFor combination therapy with Pembrolizumab only:\n\n* Serious adverse immune related adverse events (grade 3 or 4) with previous PD-1(L1) inhibitor therapy, that were symptomatic and required prolong immunosuppression (\\>6 weeks).\n* Any grade Pneumonitis and Myocarditis related to prior PD-1(L1) inhibitor therapy.\n* For subjects that received PD-1(L1) inhibitors before, there should be a washout period of at least 21 days between the last day of PD-1(L1) inhibitor and first day of study medications.\n* Subjects who relapsed after prior treatment with PD-1(L1) inhibitors. Relapsed is defined as patients having best overall response of CR or PR after treatment with a PD-1(L1) inhibitor.","80 Years",{"count":286,"type":19},242,[100,288],"PHASE2","This is a multicenter, open-label, Phase 1\u002F2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists",[291,292,24,293,220,294,224,295,111,112,296,297,298,299,300,301,302,303,304,305,306,307,27,308,309],"Head and Neck Carcinoma","Adenoid Cystic Carcinoma","Non-Small Cell Lung Cancer","Mesothelioma","Any Solid Tumors Progressed After a Prior Immunotherapy","Salivary Gland Carcinomas","Head and Neck Cancers - Salivary Gland","Head and Neck Cancers - Nasopharyngeal","Head and Neck Cancers - Throat","Small Cell Lung Cancer ( SCLC )","Lung Cancer (Locally Advanced or Metastatic)","Head and Neck Cancers - Tonsils","Head and Neck Cancers Hypopharynx","Head and Neck Cancers Larynx","Head and Neck Cancers Lip","Head and Neck Cancers Nasopharynx","Head and Neck Cancers Oral Cavity","Head and Neck Cancers Oropharynx","Head and Neck Cancers Trachea",[311,312,291,292,24,293,117,294,313,314,315,316,317,318,114,27,319,320,321,322,323,324,325,326,327,328],"TrkA","NTRK1","Pancreatic","Progression after anti PD-1\u002FPD-L1 immunotherapy","Progressed after an immunotherapy","Esophageal","SCLC","ACC","HNC","Salivary Gland Carcinoma","Nasopharyngeal","Throat","Tonsils","Hypopharynx","Larynx","Oral Cavity","Oropharynx","Trachea","2025-12-04",{"date":331,"type":32},"2025-12-11",{"date":333,"type":32},"2018-06-08",{"date":335,"type":19},"2028-06",{"name":337,"class":127},"VM Oncology, LLC",15,{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":348,"conditions":349,"keywords":350,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":364},"100575365","biomedical-innovation-for-facial-bone-reconstruction-in-oncology-bioface-pass-a-medico-economic-study-describing-the-standard-pathway-of-patients-treated-by-free-bone-flap-100575365","NCT06771336","Biomedical Innovation for Facial Bone Reconstruction in Oncology: BIOFACE PASS a Medico-economic Study Describing the Standard Pathway of Patients Treated by Free Bone Flap","Standard of Care Pathways Evaluation of Patients Treated for Facial Reconstruction After Surgery for Head and Neck Cancer, Using the Conventional Technique (Free Bone Flap): a Medico-economic Study","BIOFACE PASS","Inclusion Criteria:\n\n* Patient with oral cavity cancer or maxillary and\u002For oropharynx cancer\n* Eligible for treatment by surgery requiring a mandibulectomy or segmental maxillectomy and having a free bone flap for facial reconstruction.\n* Patient whose disease is classified Stage cT4a, N0 to N3, M0\n* Treatment with a feasible curative aim (no contraindication to optimal treatment such as surgery or chemotherapy at a curative dose)\n* Age greater than or equal to 18 years\n* Patient affiliated to a Social Security scheme in France\n* Patient having given written informed consent\n\nNon-inclusion Criteria:\n\n* Patient having any situation considered by the doctor as a reason for non-inclusion such as stenosis of the leg tripod not allowing reconstruction by fibula, one or more comorbidity(s) not allowing reconstruction by free bone flap or making this reconstruction too much risk\n* Patient having had previous radiotherapy\n* Patient with severe coagulation disorders\n* Patients deprived of liberty or under legal protection regime (curatorship and guardianship, safeguard of justice)",{"count":18,"type":19},"The purpose of this study is to describe the standard of care pathway of patients treated by free bone flap for facial mandibullar or maxillar reconstruction after surgery for head and neck cancers.",[27],[351,352,353,354],"Mandibullar or maxillar reconstruction","Care pathway","Free bone flap","Medico-economic study","2025-09-17",{"date":357,"type":32},"2025-09-22",{"date":359,"type":32},"2025-09-03",{"date":361,"type":19},"2029-12",{"name":363,"class":39},"University Hospital, Toulouse",9,{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":50,"phases":375,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":40},"100588369","telemedicine-follow-up-for-early-laryngeal-cancer-a-randomized-controlled-trial-comparing-care-close-to-home-versus-standard-of-care-100588369","NCT06940505","Telemedicine Follow-Up for Early Laryngeal Cancer: a Randomized Controlled Trial Comparing Care Close to Home Versus Standard of Care","Telemedicine Follow-up for Pre-malignant and Malignant Glottic Lesions: a Randomised Controlled Trial Study Protocol Comparing Care Close to Home Versus Standard of Care","Telemedicine","Inclusion Criteria:\n\n* patients who underwent TOLS for early stage glottic squamous cell carcinoma (T1 or carcinoma-in-situ)\n* a one-way travel time to the HNOC of ≥45 minutes (intervention group) or \\\u003C 30 minutes (control group)\n* within 2 years postoperatively\n* can speak and write Dutch\n\nExclusion Criteria:\n\n* Patients will be excluded if they continue to undergo follow-up for other (head and neck) cancers in the HNOC.",{"count":374,"type":19},140,[52],"The goal of this clinical trial is to evaluate whether Telemedicine follow-up is a satisfactory and safe alternative to traditional follow-up care for patients treated for early glottic (vocal cord) cancer, particularly those who live far from a specialized head and neck oncology centre (HNOC).\n\nThe main questions it aims to answer are:\n\nIs patient satisfaction with Telemedicine follow-up comparable to standard care?\n\nIs the safety of Telemedicine follow-up (measured by recurrence rates, complications, and survival) comparable to in-person follow-up at an HNOC?\n\nResearchers will compare patients receiving Telemedicine follow-up in a nearby hospital with standard in-person follow-up at the HNOC, to see if remote evaluation of endoscopic procedures can maintain patient satisfaction and safety outcomes.\n\nParticipants with a travel time of \\> 45 minutes from a HNOC will:\n\nBe randomly assigned to either a Telemedicine follow-up group (in a nearby hospital, by a general ENT-surgeon) or a standard of care group\n\nUndergo follow-up including HD-laryngoscopy, according to clinical guidelines\n\nHave endoscopy videos evaluated remotely by specialists at the HNOC (= Telemedicine) (intervention group only)\n\nComplete surveys including patient-reported outcomes and experience measures at baseline, 6 months, and 12 months",[27,378],"Laryngeal Carcinoma",[380,381,382,383,384,385],"head and neck cancer","follow-up","patient satisfaction","telemedicine","patient reported outcome measures","quality of life","2025-08-13",{"date":388,"type":32},"2025-08-19",{"date":390,"type":32},"2025-04-01",{"date":392,"type":19},"2027-06-01",{"name":394,"class":39},"University Medical Center Groningen",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":284,"enrollmentInfo":403,"targetDuration":4,"studyType":50,"phases":404,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":40},"100601286","a-manualized-post-traumatic-growth-intervention-for-people-with-cancer-in-greece---ic-growth-100601286","NCT07108517","A Manualized Post-Traumatic Growth Intervention for People With Cancer in Greece - IC-Growth","A Manualized Post-Traumatic Growth Intervention for People With Cancer in Greece - IC-Growth. The Overarching Aim of IC-Growth is to Promote Psychosocial Care and Support for People With Cancer Using Acceptance and Committment Therapy.","IC-Growth","Inclusion Criteria:\n\n1. Adults (≥ 18 years)\n2. Having a diagnosis of a. Breast Cancer, b. Colorectal Cancer, or c. Head and Neck Cancer.\n3. Having concluded the planned chemotherapy courses and related hospital admissions\n4. Having no more than 5 years since the initial diagnosis.\n\nExclusion Criteria:\n\n1. Being in active psychological or psychiatric treatment\n2. Having an unmanaged mental health difficulty\n3. Having a severe cognitive impairment\n4. Being unable to give informed consent\n5. Being unable to speak or read Greek\n6. Having one or more relapses\n7. Diagnosed with another type of cancer within 5 years prior to recruitment.\n8. Having less than one-year life expectancy",{"count":257,"type":19},[52],"Cancer can be a very traumatic experience for the people affected and the majority of the psychological literature focuses on this. Less proliferated and researched is the increasingly recognized fact that as a result of struggling with such traumatic adversities, some people experience what is known as post-traumatic growth (PTG). PTG not only allows them to overcome their trauma (e.g., impact of cancer) and return to pre-diagnosis functioning (e.g., health, wellbeing, employment) but also results in them going over and above their previous state (e.g., increased resilience). This renders PTG an important phenomenon that could be enhanced as part of the support people with cancer receive. IC-Growth has two interconnected paths, namely a research one and another of health policy and best practice recommendations. On the first path, is a sequence of three studies, starting with a systematic review, followed by a cross-sectional study and concludes with a randomized control trial (RCT). The systematic review and close collaboration with experts (e.g., patient associations) will lead to the development of a novel manual to facilitate PTG in groups of people with cancer. The cross-sectional study will explore relationships between variables (e.g., PTG, quality of life, biological variables, illness perceptions, distress, anxiety, depression) in people with cancer (n = 150-180). Lastly, the RCT will evaluate the intervention's effects among three different groups (breast, colorectal, and head and neck cancers, n = 50-60 per group). On the other path, is the development of health policy and best practice recommendations regarding the psychosocial support of people with cancer in Greece. The project's results will be disseminated to stakeholders who provide support to people with cancer (e.g., oncologists, surgeons, psychologists, psychiatrists), through professional associations, a conference on \"Psychosocial Support in Oncology\", and publications in scientific journals. Overall, IC-Growth is a multidisciplinary project (i.e., psychology, medical, patient organizations, health policy) and joins the clinical, research and policy fields together to workable actions leading to empowering the wider community of people with cancer and improving their care.",[192,407,27],"Colon Cancer",[409,410,411,412,413,414,415,416,417,192,23,219],"Post-Traumatic Growth (PTG)","Cancer Survivorship","Psychosocial Intervention","Acceptance and Commitment Therapy (ACT)","Quality of Life (QoL)","Biomarkers (Cortisol, CRP)","Randomized Controlled Trial (RCT","Oncology Supportive Care","Group Therapy","2025-07-31",{"date":420,"type":32},"2025-08-07",{"date":422,"type":32},"2025-05-01",{"date":424,"type":19},"2025-12-30",{"name":426,"class":39},"Centre for Research and Technology Hellas",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":50,"phases":437,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":40},"100583013","comparing-closed-face-masks-vs-surface-guided-radiation-therapy-for-head-and-neck-radiotherapy-100583013","NCT06870799","Comparing Closed Face Masks vs Surface Guided Radiation Therapy for Head and Neck Radiotherapy","Randomized Controlled Trial Comparing Closed Face Masks vs Surface Guided Radiation Therapy for Head and Neck Radiotherapy","NoMask","Inclusion Criteria:\n\n* Written informed consent according to Swiss law and ICH\u002FGCP regulations before any trial specific procedures;\n* Indication for head and neck radiotherapy irrespective of tumor type;\n* Age: ≥ 18 years old;\n* Karnofsky performance status ≥70;\n* Patients who are willing and able to comply with scheduled visits, treatment, and other trial procedures.\n\nExclusion Criteria:\n\n* Prior head and neck irradiation;\n* Women who are pregnant or breast feeding;\n* Intention to become pregnant during the course of the trial;\n* Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases;\n* Known or suspected non-compliance, drug or alcohol abuse;\n* Inability to follow the procedures of the trial, e.g. due to language problems of the participant;\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.\n* One of the following Tumor Types: Nasopharynx, Sinunasal, patients with CTV within 5 mm of eyes or spinal cord.",{"count":436,"type":19},25,[52],"At present, open-face masks are used only in patients with claustrophobic anxiety, while all other patients are still immobilized with closed masks, thereby overlooking the need for improvement in patient comfort. Closed face masks in patients undergoing head and neck irradiation have never been compared to no masks in the setting of a randomized clinical trial, but only in feasibility trials. A randomized clinical trial may establish the role of no masks in terms of patient comfort, preference and setup accuracy in all patients.",[27],[380,441,442,443],"face mask","surface guidance","radiation therapy","2025-05-16",{"date":446,"type":32},"2025-05-18",{"date":448,"type":32},"2025-05-12",{"date":450,"type":19},"2027-05",{"name":452,"class":39},"University of Zurich",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":50,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":4},"100584830","phase-2-a-prospective-multicenter-multicohort-phase-ii-study-evaluating-the-efficacy-and-safety-of-preoperative-neoadjuvant-treatment-with-a-pd-1-inhibitor-in-combination-with-chemotherapy-in-locally-advanced-laryngeal-and-hypopharyngeal-squamous-cell-carcinoma-100584830","NCT06894459","A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Patients with locally advanced laryngeal and hypopharyngeal squamous cell carcinoma who have been definitively diagnosed by histology and\u002For cytology, and whose TN staging meets: T1-4a, N0-3.\n* No prior treatment received.\n* Cisplatin-tolerant.\n* Age ≥18 years.\n* ECOG performance status of 0-1.\n* Measurable disease as defined by RECIST v1.1.\n* Normal organ function.\n* Women and men of reproductive potential must agree to use appropriate contraceptive methods throughout the study period and for 180 days after the last study treatment.\n* Male participants must not donate sperm during the entire study period and for 180 days after the last study treatment.\n\nExclusion Criteria:\n\n* T stage is T4b.\n* Presence of distant metastasis.\n* Received live vaccines within 30 days prior to enrollment.\n* Diagnosed with an immunodeficiency or received systemic corticosteroid treatment or any other form of immunosuppressive therapy within 7 days prior to enrollment.\n* Have radiologically detectable (even if asymptomatic and\u002For previously treated) central nervous system metastases and\u002For carcinomatous meningitis.\n* Have not fully recovered from surgery or from toxicities or complications due to interventions before starting the study.\n* Have a history of allogeneic tissue\u002Fsolid organ transplantation.\n* Have had a severe hypersensitivity reaction (≥Grade 3) to PD-1 inhibitors, chemotherapy, or any of their excipients, or radiotherapy.\n* Have an active autoimmune disease that has required systemic therapy within the past 2 years.\n* Have a history of (non-infectious) pneumonitis that required treatment with corticosteroids.\n* Have a history of infection with the Human Immunodeficiency Virus (HIV).\n* Have a medical history that could confound study results or interfere with the participant during the study period.\n* Have a known history of psychiatric disorders or substance abuse.",{"count":257,"type":19},[288],"Head and neck squamous cell carcinoma (HNSCC) refers to a series of tumors that occur in the head and neck region, including the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid gland, and salivary glands. Malignant tumors of the head and neck account for approximately 19.9% to 30.2% of all tumors in the body, ranking sixth in incidence among all malignant tumors, with over 90% being squamous cell carcinoma in terms of pathological type. The treatment of head and neck squamous cell carcinoma is primarily surgical. Early-stage cases can achieve a cure through simple surgical resection or radiotherapy. For locally advanced and late-stage cases, a combination of surgery with radiotherapy or chemotherapy can yield satisfactory therapeutic effects. However, most patients with head and neck tumors present at a locally advanced (Stage III to IVB) or late stage, possibly having lost the opportunity for surgery and can only opt for a comprehensive treatment mainly based on radiochemotherapy. Current data show that with standard treatment, the 5-year survival rates for patients with early-stage, locally advanced, and metastatic head and neck squamous cell carcinoma are 80%, 50%, and 25%, respectively. Fifty to sixty percent of newly diagnosed subjects cannot be cured and experience recurrence or metastasis within 3 years. For patients with recurrent or metastatic disease after first-line treatment failure, the median survival time with chemotherapy is only 6 to 9 months, with a 1-year survival rate of 5% to 33% and a 5-year survival rate of merely 3.6%. Laryngeal cancer and hypopharyngeal cancer hold unique significance among head and neck tumors because they not only threaten patients' lives but can also significantly affect their quality of life, particularly the preservation of laryngeal function. Laryngeal function includes voice production, swallowing, and breathing, and the loss of these functions can lead to a severe decline in quality of life. Traditionally, surgical resection has been the main treatment for these cancers, but total laryngectomy can result in permanent voice loss and significant psychological and social impacts. Therefore, how to effectively control the tumor while preserving laryngeal function has become an important goal of treatment.\n\nPD-L1 is a key negative regulator of self-reactive T cells and plays a role in maintaining peripheral immune tolerance and suppressing autoimmunity in various ways, leading to T cell exhaustion and dysfunction, and allowing tumor cells to evade immune surveillance. PD-1\u002FPD-L1 monoclonal antibodies restore the function of tumor-specific T cells by blocking the binding of PD-1 to PD-L1, thereby enhancing antitumor immunity and are now used to treat a variety of tumors. The efficacy of PD-1 inhibitors as neoadjuvant therapy in head and neck squamous cell carcinoma is not yet clear. However, given the good therapeutic effects of immunotherapy in head and neck squamous cell carcinoma, induction therapy with PD-1 inhibitors is considered to have promising clinical application prospects.\n\nIn summary, we hypothesize that compared with the traditional TPF (docetaxel, cisplatin, and fluorouracil) neoadjuvant chemotherapy regimen, a PD-1 inhibitor combined with chemotherapy regimen may be safer and more effective and easier to apply in clinical practice. At present, there are no reports of studies on the use of PD-1 inhibitors combined with chemotherapy regimens for locally advanced, resectable head and neck squamous cell carcinoma patients, either domestically or internationally. We plan to investigate the efficacy and safety of neoadjuvant treatment with PD-1 inhibitors combined with chemotherapy for resectable head and neck squamous cell carcinoma patients in China, to provide a basis for future neoadjuvant treatment regimens.",[27],"2025-04-27",{"date":465,"type":32},"2025-04-30",{"date":467,"type":19},"2025-05-08",{"date":469,"type":19},"2028-12-01",{"name":471,"class":39},"Beijing Tongren Hospital",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":15,"minAge":479,"maxAge":284,"enrollmentInfo":480,"targetDuration":4,"studyType":50,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":40},"100316042","strataxrt-vs-standard-clinical-practice-for-the-prevention-of-acute-dermatitis-in-head-and-neck-cancers-patients-100316042","NCT03394417","StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Head and Neck Cancers Patients","StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Patients Receiving Concurrent Chemoradiation for Head and Neck Cancers","Inclusion Criteria:\n\n* patients who are 21 years of age or older\n* histological diagnosis of head and neck carcinoma available\n* patients who are to be treated with concurrent chemoradiation\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3\n* no known allergy to StrataXRT or silicone\n* able to give written informed consent, or have written consent given on their behalf\n\nExclusion Criteria:\n\n* patients who cannot apply the skin product or have it administered to them\n* patients with comorbidities and\u002For on medications that may alter the response of the skin e.g. connective tissue disorder\n* patients with existing rashes or wounds in the radiation field at baseline\n* patients receiving concurrent cetuximab during radiotherapy\n* previous radiotherapy to the head and neck region\n* female patients who are pregnant or breast feeding\n* unable to give written informed consent , or are unable to have written consent given on their behalf","21 Years",{"count":481,"type":19},100,[52],"This is a phase IV, prospective, double-blind, randomized controlled trial with 2 study arms. The study population will be patients receiving chemoradiation for head and neck carcinomas, the majority of whom will be outpatients unless they require inpatient supportive care during treatment.\n\nThere will be a 12 to 14-week longitudinal follow-up with 9 assessments conducted during this follow-up.\n\nThe estimated duration of recruitment will be 6-8 years.\n\nIntervention group If a patient is allocated to the intervention group following randomization, the patient will be treated with StrataXRT.\n\nControl group If a patient is allocated to the control group following randomization, the patient will be treated with standard clinical practice which consists of aqueous cream.",[27,485],"Acute Radiation Dermatitis","2024-12-08",{"date":488,"type":32},"2024-12-12",{"date":490,"type":32},"2018-11-08",{"date":492,"type":19},"2027-06",{"name":494,"class":39},"National University Hospital, Singapore",{"id":496,"slug":497,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":503,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":50,"phases":506,"briefSummary":507,"conditions":508,"keywords":514,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":526,"locationsCount":528},"100466092","comprehensive-outcomes-for-after-cancer-health-100466092","NCT05349227","Comprehensive Outcomes for After Cancer Health","Comprehensive Outcomes for After Cancer Health (COACH): the Feasibility and Impact of an MHealth Augmented Coaching Program for Self-Management in Cancer Survivors","COACH","Inclusion Criteria:\n\n1. Have primary diagnosis of cancer;\n2. Are within 1 year of completion of primary therapy OR have a diagnosis of metastatic cancer\n\n   1. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy\n   2. For individuals with metastatic cancer, individuals may be included provided they completed primary therapy for a de novo diagnosis of metastatic disease within the last year, are within one year of completion of initial therapy for their primary cancer diagnosis for which disease progression has occurred, or who are within one year of receiving treatment for metastatic disease (including individuals currently receiving treatment).\n3. Are aged 18 years and older;\n4. Can read and consent to participate in the trial;\n5. Can read and speak English;\n6. Can complete study follow-up at pre-specified intervals;\n7. Have access to mobile technology (e.g. a smart phone or tablet) that would allow engagement in digital health coaching for the collection of PROs and wearable data.\n\nExclusion Criteria:\n\n1. Have a cognitive impairment (as assessed by their provider) that would prohibit the individual from engaging with the digital health coaching program or complete study assessments;\n2. Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to engage in physical activity (as assessed by their provider)\n3. Have a life expectancy of \\<6 months, and\u002For\n4. Are on active treatment for relapsed disease. a. Individuals with disease progression or relapse which occurs following their consent to participate will be given the option to continue on study if they wish to do so. Data from individuals experiencing disease progression or relapse will be grouped for sub-analysis to explore if and how relapse impacts study outcomes.\n\nHealthy Volunteers must:\n\n1. Be adults aged 18 years or older or the age of majority in their state of residence, whichever is older.\n2. Must reside in the same dwelling as the patient participant\n3. Can read and consent to participate in the trial;\n4. Can read and speak English;\n5. Can complete study follow-up at pre-specified intervals;",true,{"count":505,"type":19},625,[52],"This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and clinical outcomes, as well as wearable data. Those in the control group will be monitored via patient reported and clinical outcomes as well as wearable data for the first 6 months followed by 6 months of digital health coaching. Both groups will collect fecal microbiome samples at enrollment and month 6. The study aims to explore if and how digital health coaching may be used to enhance outcomes for individuals following completion of primary cancer therapy.",[222,192,24,223,509,510,27,511,512,513,235],"Survivorship","Endometrial Cancer","Prostate Cancers","Geriatric Oncology","Metastatic Breast Cancer",[515,516,517,518,519],"Patient Reported Outcome Measures","Physical Activity","Digital Coaching","Microbiome","Wearables","2024-12-06",{"date":522,"type":32},"2024-12-11",{"date":524,"type":32},"2022-06-23",{"date":450,"type":19},{"name":527,"class":127},"Pack Health",7,{"id":530,"slug":531,"hasResults":11,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":4},"100563592","evaluation-clinique-des-performances-du-dispositif-daide--la-chirurgie-dyameo-100563592","NCT06618170","Evaluation Clinique Des Performances Du Dispositif D'Aide À La Chirurgie Dyameo","ETCETERA","Inclusion Criteria:\n\n* Confirmed diagnosis of squamous cell carcinoma of the oral cavity, pharynx and\u002For larynx\n* Planned standard surgery with curative intent for squamous cell carcinoma\n* Planned surgery includes the performance of extemporaneous biopsies\n* Age ≥ 18 years\n* Affiliation to a social security scheme\n\nExclusion Criteria:\n\n* Medical or psychiatric conditions that compromise the patient\\'s ability to understand the research in which he or she is participating\n* Persons of full age subject to a legal protection measure (guardianship or curatorship) or unable to express their non-objection.\n* Uncontrolled concomitant medical conditions\n* Having received an investigational medicinal product in the 30 days prior to the operation\n* History of treatment with anti-EGFR monoclonal antibodies.\n* Previously demonstrated absence of EGFR expression by tumour cells.",{"count":537,"type":19},80,"During the surgical removal of head and neck tumours, the correct determination of the boundary between healthy and tumour tissue is critical. It is essential to remove all tumour tissue while preserving as much of the surrounding healthy tissue as possible. Today, surgeons use frozen sections to confirm their decision. Dyameo has developed a device that can identify the presence of tumour markers on the surface of tissue in a matter of seconds, simply by placing the end of a fibre-optic probe in contact with the tissue. This device should enable the surgeon to identify the presence of tumour cells at the margin of the removed tumour.\n\nThe aim of this study is to measure the performance of this device. The surgeon will carry out his operation according to his own routine. After collecting tissue for frozen section analysis, he will analyse the tumour specimen using the Dyameo device. After the operation, histological analysis of the removed tumour will enable the precision of the device to be measured and compared with that of the extemporaneous biopsies to guide the surgeon\\'s intervention.",[27],[541,542,543,544],"guided surgery","head and neck","carcinoma","surgical margin","2024-09-30",{"date":547,"type":32},"2024-10-02",{"date":549,"type":19},"2024-11",{"date":551,"type":19},"2025-07",{"name":553,"class":127},"Dyameo",{"id":555,"slug":556,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":50,"phases":563,"briefSummary":564,"conditions":565,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":40},"100557946","phase-1-scg142-tcr-t-cells-for-human-papillomavirus-associated-carcinomas-100557946","NCT06544720","SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas","A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas","Key Inclusion Criteria:\n\n1. Greater than or equal to 18 years of age\n2. HPV associated carcinomas\n3. Patients must have at least one measurable lesion defined by RECIST 1.1\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\nKey Exclusion Criteria:\n\n1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.\n2. Patients with active autoimmune diseases.\n3. Patient has a known active Hepatitis B or Hepatitis C.\n4. Other severe medical conditions that may limit subject\\'s participation in this trial.",{"count":562,"type":19},18,[100],"A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.",[566,567,27,568,569,570,571,572],"Human Papillomavirus Associated Carcinomas","Cervical Cancer","Anal Cancer","Vulva Cancer","Vaginal Cancer","Penile Cancer","HPV-Related Malignancy","2024-08-06",{"date":575,"type":32},"2024-08-09",{"date":577,"type":32},"2023-08-02",{"date":579,"type":19},"2026-12-31",{"name":581,"class":39},"The Affiliated Hospital of Qingdao University",{"id":583,"slug":584,"hasResults":11,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":589,"enrollmentInfo":590,"targetDuration":4,"studyType":50,"phases":592,"briefSummary":593,"conditions":594,"keywords":596,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":4},"100543606","phase-1-crte7a2-01-tcr-t-cells-for-hpv-16-positive-advanced-cancers-100543606","NCT06358053","CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers","A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cells in HLA-A*02:01+ Subjects With HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers and Other Solid Tumors","Inclusion Criteria:\n\n1\\. Age \\>18 years and 65 years. 2. Patients with advanced solid tumors (such as cervical cancer, head and neck tumors, anal cancer, and other malignancies) who have failed standard treatment confirmed by histology and\u002For cytology, or who are intolerant to such treatment, and for whom there is no effective therapy available after standard treatment failure are considered as end-stage patients. Specifically for:\n\n1. Cervical cancer: a) Patients who have previously failed at least second-line systemic therapy (including at least one platinum-based regimen or anti-angiogenic therapy) and have shown disease progression or intolerance confirmed by pathological or radiological examination during or after the most recent treatment course, and are not amenable to treatment with surgery or radiotherapy, with no standard treatment options currently available for recurrent or metastatic cervical cancer.\n2. Nasopharyngeal cancer: a) Patients who have previously failed at least third-line systemic therapy or are intolerant, not amenable to treatment with surgery or radiotherapy, with no standard treatment options currently available for recurrent or metastatic nasopharyngeal cancer; b) EB virus negative.\n3. Head and neck squamous cell carcinoma: a) Patients who have previously failed at least second-line systemic therapy or are intolerant, with no standard treatment options currently available for recurrent or metastatic head and neck squamous cell carcinoma (non-nasal).\n\n3\\. Confirmation of HPV16 positive and HLA-A\\*02:01 allele. 4. ECOG performance status of 0-1. 5. Estimated life expectancy ≥ 3 months. 6. Patients must have at least one measurable lesion defined by RECIST 1.1. 7. Female patients of childbearing age must undergo a serum pregnancy test within 7 days prior to study treatment and the results must be negative, and are willing to use a very effective and reliable method of contraception from screening through 6 months after the last dose of study treatment.\n\n8\\. The patient must be willing to sign the informed consent form and have a good anticipation of compliance with study procedure.\n\nExclusion Criteria:\n\n1. Patient received any genetically modified T cell therapy.\n2. Patient is being treated with T cell immunosuppressive agent （such as cyclophosphamide, FK506,tripterygium glycosides） or T cell immunoagonist.\n3. Patients received chemotherapy, targeted therapy, immunotherapy, or other investigational agents within 2 weeks and received radiotherapy within 4 weeks before apheresis.\n4. Patients have any organ system function impairment as defined below:\n\n   * leukocytes\\\u003C3.0 x 109\u002FL\n   * absolute neutrophil count \\>1.5 x 109\u002FL\n   * hemoglobin\\\u003C90g\u002FL\n   * platelets \\\u003C100 x 1010\u002FL\n   * lymphocytes\\\u003C0.5 x 109\u002FL\n   * percentage of lymphocytes\\\u003C15%\n   * creatinine\\>1.5×ULN or creatinine clearance \\\u003C50mL\u002Fmin\n   * total bilirubin\\>3×ULN; ALT\u002FAST\\>3×ULN (patients with liver metastasis,\\>5×ULN)\n   * INR\\>1.5×ULN; APTT\\>1.5×ULN\n   * SpO2≤90%\n\n6\\. Patinets has serious medical conditions, disorders, and \u002F or comorbidities, including, but are not limited to: severe heart disease, cerebrovascular disease, epileptic seizures, uncontrolled diabetes (CTCAE 5.0: FBG ≥ 2 grade), active infection, active digestive tract Ulcer, gastrointestinal bleeding, intestinal obstruction, pulmonary fibrosis, renal failure, respiratory failure.\n\n7\\. Patient has a severe cardiovascular disease with 6 months before screening, including, but are not limited to, myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Heart failure NYHA grade Ⅲ or Ⅳ.\n\n8\\. Left Ventricular Ejection Fractions (LVEF) \\\u003C50%. 9. Patient has a known active brain metastases. 10. Patient has a known myelodysplastic syndrome (MDS) or lymphoma. 11. Patient has a known active autoimmune disease, including , but are not limited to, acquired or congenital immunodeficiency disease, allogeneic organ transplantation, autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease.\n\n12\\. Patient has a known active Hepatitis B or Hepatitis C. 13. Patient has a history of Human Immunodeficiency Virus (HIV) . 14. Patient has a history of syphilis. 15. Pregnant or lactating women. 16. Patient has a known active mental and neurological diseases. 17. The principal investigator judged that it is not suitable to participate in this clinical study.","65 Years",{"count":591,"type":19},24,[100],"A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A\\*02:01+ Subjects HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine RP2D of CRTE7A2-01 TCR-T cell injection.",[567,568,27,595],"Other Solid Tumors",[597,598,599,600,601,602,603],"HPV","E7","immunotherapy","T cell","Adoptive cell therapy","T cell receptor","TCR","2024-04-06",{"date":606,"type":32},"2024-04-10",{"date":608,"type":19},"2024-04-15",{"date":610,"type":19},"2028-04-30",{"name":612,"class":127},"Corregene Biotechnology Co., Ltd"]